
Loading, please wait...

Loading, please wait...

The recent advancement in nanofluidic biosensing technology offers a new path for medical diagnostics. Researchers developed ionic transistors using single sub-10 nm nanopores. These devices consist of van der Waals (vdW) heterostructures. Notably, they feature internal gate electrodes made of few-layer graphene. This design allows for precise control of ionic transport at very low voltages. Consequently, these tools may soon revolutionize how we monitor biological signals.
Traditional nanofluidic devices often require gate voltages exceeding 1V. However, the new vdW nanopores operate effectively at just 0.3V. This low-power requirement is critical for portable medical devices. Furthermore, these transistors function at near-physiological salt concentrations. Most previous models only worked in sub-millimolar environments. Therefore, this breakthrough bridges the gap between laboratory physics and clinical application. Importantly, it allows the device to interact directly with human fluids like blood.
The devices utilize negatively charged hexagonal boron nitride (hBN) walls. These walls dominate transport at salt levels below 100 mM. Specifically, a negative gate voltage enriches ion concentrations to enhance current. In contrast, a positive voltage creates a depletion zone. This zone suppresses ionic transport effectively. Additionally, the researchers used molecular dynamics simulations to study water behavior. They found that surface charges suppress the permittivity of interfacial water. This knowledge helps engineers sculpt local potential. Therefore, it enhances the sensitivity of future sensors.
This technology addresses a key need in modern medicine. Low-power ionic circuits can power implantable biosensors. Moreover, the ability to rectify ion current allows for more complex logic operations within the body. Scientists can now design sensors that respond to specific molecular cues. This could lead to real-time monitoring of electrolytes or hormones. Ultimately, this nanofluidic biosensing technology provides the foundation for biocompatible electronic interfaces.
Van der Waals nanopores use atom-thin materials like graphene and hBN. This structure allows for an internal gate electrode. Consequently, the device can control ion flow at much lower voltages than standard solid-state pores.
Medical samples like blood or interstitial fluid have high salt concentrations. Most electronic biosensors fail in these environments. This new nanofluidic biosensing technology maintains its function at 100 mM KCl, making it biocompatible.
The transistors operate at gate voltages as low as 0.3V. This significantly reduces energy consumption compared to previous 1V models. Therefore, it is ideal for battery-operated or self-powered diagnostic tools.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or endorse specific diagnostic products. Refer to the latest local and national guidelines for clinical practice.
References
Barajas-Aguilar AH et al. Electrostatic Gating of Ionic Conductance through Heterogeneous van der Waals Nanopores. ACS Nano. 2026 Jun 12. doi: 10.1021/acsnano.6c03174. PMID: 42284080.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers have developed nanofluidic ionic transistors using van der Waals heterostructures. These devices operate at near-physiological salt concentrations with low gate voltages. This advancement in nanofluidic biosensing technology paves the way for low-power, biocompatible diagnostic tools.
2 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today